Transcriptomic profiling of sporadic Alzheimer's disease patients

被引:14
作者
Caldwell, Andrew B. [1 ]
Anantharaman, Balaji G. [1 ]
Ramachandran, Srinivasan [1 ]
Nguyen, Phuong [2 ]
Liu, Qing [2 ,3 ]
Trinh, Ivy [2 ,4 ]
Galasko, Douglas R. [2 ]
Desplats, Paula A. [2 ,5 ]
Wagner, Steven L. [2 ,6 ]
Subramaniam, Shankar [1 ,7 ,8 ,9 ]
机构
[1] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Dept Obstet Gynecol & Reprod Sci, La Jolla, CA 92093 USA
[4] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA
[5] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA
[6] VA San Diego Healthcare Syst, La Jolla, CA USA
[7] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
[8] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA
[9] Univ Calif San Diego, Dept Comp Sci & Engn, La Jolla, CA 92093 USA
关键词
D O I
10.1186/s13041-022-00963-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Alzheimer's disease (AD) manifested before age 65 is commonly referred to as early-onset AD (EOAD) (Reitz et al. Neurol Genet. 2020;6:e512). While the majority (> 90%) of EOAD cases are not caused by autosomal-dominant mutations in PSEN1, PSEN2, and APP, they do have a higher heritability (92-100%) than sporadic late-onset AD (LOAD, 70%) (Wingo et al. Arch Neurol. 2012;69:59-64, Fulton-Howard et al. Neurobiol Aging. 2021;99:101.e1-101.e9). Although the endpoint clinicopathological changes, i.e., A beta plaques, tau tangles, and cognitive decline, are common across EOAD and LOAD, the disease progression is highly heterogeneous (Neff et al. Sci Adv Am Assoc Adv Sci. 2021;7:eabb5398). This heterogeneity, leading to temporally distinct age at onset (AAO) and stages of cognitive decline, may be caused by myriad combinations of distinct disease-associated molecular mechanisms. We and others have used transcriptome profiling in AD patient-derived neuron models of autosomal-dominant EOAD and sporadic LOAD to identify disease endotypes (Caldwell et al. Sci Adv Am Assoc Adv Sci. 2020;6:eaba5933, Mertens et al. Cell Stem Cell. 2021;28:1533-1548.e6, Caldwell et al. Alzheimers Demen. 2022). Further, analyses of large postmortem brain cohorts demonstrate that only one-third of AD patients show hallmark disease endotypes like increased inflammation and decreased synaptic signaling (Neff et al. Sci Adv Am Assoc Adv Sci. 2021;7:eabb5398). Areas of the brain less affected by AD pathology at early disease stages-such as the primary visual cortex-exhibit similar transcriptomic dysregulation as those regions traditionally affected and, therefore, may offer a view into the molecular mechanisms of AD without the associated inflammatory changes and gliosis induced by pathology (Haroutunian et al. Neurobiol Aging. 2009;30:561-73). To this end, we analyzed AD patient samples from the primary visual cortex (19 EOAD, 20 LOAD) using transcriptomic signatures to identify patient clusters and disease endotypes. Interestingly, although the clusters showed distinct combinations and severity of endotypes, each patient cluster contained both EOAD and LOAD cases, suggesting that AAO may not directly correlate with the identity and severity of AD endotypes.
引用
收藏
页数:7
相关论文
共 37 条
[1]  
[Anonymous], 1976, Geriatric psychiatry
[2]   Gene Ontology: tool for the unification of biology [J].
Ashburner, M ;
Ball, CA ;
Blake, JA ;
Botstein, D ;
Butler, H ;
Cherry, JM ;
Davis, AP ;
Dolinski, K ;
Dwight, SS ;
Eppig, JT ;
Harris, MA ;
Hill, DP ;
Issel-Tarver, L ;
Kasarskis, A ;
Lewis, S ;
Matese, JC ;
Richardson, JE ;
Ringwald, M ;
Rubin, GM ;
Sherlock, G .
NATURE GENETICS, 2000, 25 (01) :25-29
[3]   ASSOCIATION BETWEEN QUANTITATIVE MEASURES OF DEMENTIA AND OF SENILE CHANGE IN CEREBRAL GREY MATTER OF ELDERLY SUBJECTS [J].
BLESSED, G ;
TOMLINSON, BE ;
ROTH, M .
BRITISH JOURNAL OF PSYCHIATRY, 1968, 114 (512) :797-+
[4]   Near-optimal probabilistic RNA-seq quantification [J].
Bray, Nicolas L. ;
Pimentel, Harold ;
Melsted, Pall ;
Pachter, Lior .
NATURE BIOTECHNOLOGY, 2016, 34 (05) :525-527
[5]   Molecular genetics of early-onset Alzheimer's disease revisited [J].
Cacace, Rita ;
Sleegers, Kristel ;
Van Broeckhoven, Christine .
ALZHEIMERS & DEMENTIA, 2016, 12 (06) :733-748
[6]   Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease [J].
Caldwell, Andrew B. ;
Liu, Qing ;
Zhang, Can ;
Schroth, Gary P. ;
Galasko, Douglas R. ;
Rynearson, Kevin D. ;
Tanzi, Rudolph E. ;
Yuan, Shauna H. ;
Wagner, Steven L. ;
Subramaniam, Shankar .
ALZHEIMERS & DEMENTIA, 2022, 18 (11) :2117-2130
[7]   Dedifferentiation and neuronal repression define familial Alzheimer's disease [J].
Caldwell, Andrew B. ;
Liu, Qing ;
Schroth, Gary P. ;
Galasko, Douglas R. ;
Yuan, Shauna H. ;
Wagner, Steven L. ;
Subramaniam, Shankar .
SCIENCE ADVANCES, 2020, 6 (46)
[8]   Enrichr: interactive and collaborative HTML']HTML5 gene list enrichment analysis tool [J].
Chen, Edward Y. ;
Tan, Christopher M. ;
Kou, Yan ;
Duan, Qiaonan ;
Wang, Zichen ;
Meirelles, Gabriela Vaz ;
Clark, Neil R. ;
Ma'ayan, Avi .
BMC BIOINFORMATICS, 2013, 14
[9]   ReMap 2018: an updated atlas of regulatory regions from an integrative analysis of DNA-binding ChIP-seq experiments [J].
Cheneby, Jeanne ;
Gheorghe, Marius ;
Artufel, Marie ;
Mathelier, Anthony ;
Ballester, Benoit .
NUCLEIC ACIDS RESEARCH, 2018, 46 (D1) :D267-D275
[10]   Reactome: a database of reactions, pathways and biological processes [J].
Croft, David ;
O'Kelly, Gavin ;
Wu, Guanming ;
Haw, Robin ;
Gillespie, Marc ;
Matthews, Lisa ;
Caudy, Michael ;
Garapati, Phani ;
Gopinath, Gopal ;
Jassal, Bijay ;
Jupe, Steven ;
Kalatskaya, Irina ;
Mahajan, Shahana ;
May, Bruce ;
Ndegwa, Nelson ;
Schmidt, Esther ;
Shamovsky, Veronica ;
Yung, Christina ;
Birney, Ewan ;
Hermjakob, Henning ;
D'Eustachio, Peter ;
Stein, Lincoln .
NUCLEIC ACIDS RESEARCH, 2011, 39 :D691-D697